ImmunityBio advances NMIBC and NSCLC treatments with promising trial data and plans 2025 FDA submissions for innovative ...

Johnson & Johnson JNJ has initiated a rolling submission with the FDA seeking approval for TAR-200, its investigational ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced significant progress in its ongoing ...

CG Oncology's stock has dropped 40% since its IPO peak, driven by profit-taking and competitive concerns despite promising ...

The PD-1 receptor, a major immune checkpoint inhibitor whose signaling is the target of multiple blockbuster anticancer drugs, differs functionally between rodents and humans in previously unknown ...

Pfizer's Phase 3 CREST trial results highlight the efficacy of sasanlimab combined with BCG in treating high-risk non-muscle invasive bladder cancer.

The antibody treatment, sasanlimab, in combination with Bacillus Calmette-Guérin (BCG) vaccine met the main goal of the study ...

NYSE:PFE) Pfizer's Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer ...

Pfizer’s “golden egg” has hatched. The subcutaneous PD-1 inhibitor improved outcomes when added to the standard of care in ...

( NASDAQ: IBRX ), a leading immunotherapy company, today announced the unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code assigned by the ...

Travelers provides the best car insurance in California, according to NerdWallet’s analysis. Many, or all, of the products featured on this page are from our advertising partners who compensate ...

New safeguards against artificial intelligence deepfakes. The California Legislature passed hundreds of bills in 2024, many of which go into effect on Jan. 1 and touch nearly every aspect of life ...